

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ZJ**

**中基長壽科學**

ZHONG JI LONGEVITY SCIENCE

**Zhong Ji Longevity Science Group Limited**

**中基長壽科學集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE  
INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2021**

Reference is made to the interim report of Zhong Ji Longevity Science Group Limited (the “**Company**”) for the six months ended 30 June 2021 (the “**2021 Interim Report**”). Capitalised terms used herein shall have the same meanings as those defined in the 2021 Interim Report unless the context requires otherwise.

In addition to the information disclosed in the paragraph “Share Options” in the 2021 Interim Report, the Board wishes to provide the following additional information in respect of the grant of the share options on 31 December 2020:

The 386,800,000 share options were granted to ten (10) consultants of the Company (the “**Consultant(s)**”). Each Consultant is entitled 38,680,000 share options.

The Board had set out performance targets for the Consultants as part of the conditions for grant of the Options. Such performance targets dictated that each of the consultants would create revenue for the Group of a certain amount within three years from the grant of the share options, which includes introducing clients, investors and potential business opportunities to the Company, recommending and advising on potential acquisition projects and assisting and advising in potential fund raising activities.

To the best knowledge of the Directors, the duties of the Consultants are as follows:

- (1) Consultant A — introduce partners and investors to the Company
- (2) Consultant B — provide financial advice and strategic business strategies to the Company
- (3) Consultant C — introduce clients to the Company
- (4) Consultant D — introduce clients to the Company
- (5) Consultant E — introduce clients to the Company
- (6) Consultant F — introduce clients to the Company
- (7) Consultant G — introduce clients and investors to the Company
- (8) Consultant H — introduce clients to the Company
- (9) Consultant I — introduce clients to the Company
- (10) Consultant J — Mr. LI Xiaoshuang: introduce clients to the Company

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, save for Mr. LI Xiaoshuang, who was an independent third party at the time of the grant of the share options, and subsequently resigned as consultant and was appointed as an executive Director on 30 August 2021, all the remaining consultants are independent third parties of the Company. None of the Consultants holds share options entitling them to subscribe for Shares exceeding 1% of the total issued Shares of the Company as at the date of grant.

The Board confirmed that the above additional information does not affect other information contained in the 2021 Interim Report and, save as disclosed above, the contents of the 2021 Interim Report remain unchanged.

By order of the Board  
**Zhong Ji Longevity Science Group Limited**  
**Yan Li**  
*Chairman*

Hong Kong, 23 November 2021

As at the date of this announcement, the Directors are:

*Executive Directors*

Mr. Yan Li (*Chairman*)

Mr. Wang Hongxin (*Chief Executive Officer*)

Mr. Li Xiaoshuang

Ms. Cao Xie Qiong

*Independent non-executive Directors*

Mr. Tam Ho Leung Simon

Ms. Wang Weixia

Mr. Chai Nan

*Non-executive Directors*

Dr. He Yiwu

Ms. Choi Ngai Wah

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*